{
    "clinical_study": {
        "@rank": "110936", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes."
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Other", 
                "description": "With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care)."
            }
        ], 
        "brief_summary": {
            "textblock": "The debate about tight glycemic control (TGC) in the operating room and on the intensive\n      care unit is ongoing, especially in cardio-surgical patients treated with blood\n      cardioplegia, due to high blood glucose levels during operations and subsequent high rates\n      of sternal wound infections. We showed in a feasibility study that early computer based\n      insulin therapy starting in the operating room is a safe therapy that allows to better\n      warrant normoglycemia in patients undergoing major cardiac surgery with the use of blood\n      cardioplegia."
        }, 
        "brief_title": "Computerized Tight Glycemic Control in Cardiac Surgery", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hyperglycemia", 
        "condition_browse": {
            "mesh_term": "Hyperglycemia"
        }, 
        "detailed_description": {
            "textblock": "Patients are enrolled and randomized into 3 groups. Start of therapy is determined as the\n      beginning of cardiopulmonary bypass. Group A: Therapy with computer-based algorithm and\n      measurement of blood glucose every 30 min. Group B: Measurement of blood glucose every 15\n      min using the identical computer-based algorithm. Group C: Conventional therapy using a\n      fixed insulin dosing scheme. End of therapy is defined as discharge from ICU."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients over 18 scheduled for elective cardiac surgery with the use of\n             cardiopulmonary bypass and blood cardioplegia\n\n        Exclusion Criteria:\n\n          -  under 18 years of age, or if patients had a premedical history of steroid therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886365", 
            "org_study_id": "PV3388"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "description": "Computerized algorithmic application of insulin", 
                "intervention_name": "Space GlucoseControl System, B. Braun, Melsungen, Germany", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Group C", 
                "description": "Routine care", 
                "intervention_name": "Conventional therapy with a fixed insulin dosing scheme", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Computer based glycemic control, insulin, blood glucose", 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany", 
                    "zip": "20246"
                }, 
                "name": "University Medical Center Hamburg-Eppendorf"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Perioperative Glycemic Control With a Computerized Algorithm vs. Conventional Glycemic Control in Cardio-surgical Patients Undergoing Cardiopulmonary Bypass With Blood Cardioplegia", 
        "overall_official": {
            "affiliation": "University Medical Center Hamburg-Eppendorf, Germany", 
            "last_name": "Daniel A Reuter, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Ministry of Education and Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint was defined as the time within a given blood glucose corridor from 80 - 150 mg/dl during therapy", 
            "measure": "Time within a blood glucose corridor of 80 - 150 mg/dl", 
            "safety_issue": "No", 
            "time_frame": "From start of cardiopulmonary bypass during surgery until discharge from ICU, which is approximately after 48 -72 hrs."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886365"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
            "investigator_full_name": "Prof. Dr. med. Daniel Reuter", 
            "investigator_title": "Professor of anesthesiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Secondary endpoints were the number of hypoglycemic events defined as blood glucose levels under 80 mg/dl", 
            "measure": "Hypoglycemic events", 
            "safety_issue": "No", 
            "time_frame": "From beginning of cardiopulmonary bypass during surgery until discharge from the ICU, which is approximately after 48-72 hrs."
        }, 
        "source": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
        "sponsors": {
            "collaborator": {
                "agency": "B. Braun Melsungen AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}